Presentation
5 March 2021 TRIPODD: a novel fluorescence imaging platform for in situ measurement of drug distribution and proteomic therapeutic response
Nathan P. McMahon, Allison Solanki, Lei Wang, Jocelyn A. Jones, Kimberly S. Samkoe, Kenneth M. Tichauer, Summer L. Gibbs
Author Affiliations +
Abstract
Personalized molecularly targeted therapy has largely not lived up to its promise of providing curative therapies due to a lack of durable therapeutic response driven by a lack of drug target engagement (i.e. sublethal drug delivery to the tumor) and cell signaling reprogramming as a mechanism of acquired resistance. To simultaneously measure both of these factors, we have developed and optimized a fluorescence imaging platform, Therapeutic Response Imaging through Proteomic and Optical Drug Distribution (TRIPODD), resulting in the only methodology capable of simultaneous quantification of single-cell DTE and protein expression with preserved spatial context within a tumor.
Conference Presentation
© (2021) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Nathan P. McMahon, Allison Solanki, Lei Wang, Jocelyn A. Jones, Kimberly S. Samkoe, Kenneth M. Tichauer, and Summer L. Gibbs "TRIPODD: a novel fluorescence imaging platform for in situ measurement of drug distribution and proteomic therapeutic response", Proc. SPIE 11624, Visualizing and Quantifying Drug Distribution in Tissue V, 116240L (5 March 2021); https://doi.org/10.1117/12.2582773
Advertisement
Advertisement
KEYWORDS
Luminescence

Proteins

In situ metrology

Tumors

Tissues

Medicine

Receptors

Back to Top